Literature DB >> 8872362

Effects of SCA40 on human isolated bronchus and human polymorphonuclear leukocytes: comparison with rolipram, SKF94120 and levcromakalim.

J Cortijo1, V Villagrasa, C Navarrete, C Sanz, L Berto, A Michel, P A Bonnet, E J Morcillo.   

Abstract

1. SCA40 (0.1 nM-0.1 mM) produced concentration-dependent suppression of the spontaneous tone of human isolated bronchus (-log EC50 = 6.85 +/- 0.09; n = 10) and reached a maximal relaxation similar to that of theophylline (3 mM). The potency (-log EC50 values) of SCA40 compared to other relaxants was rolipram (7.44 +/- 0.12; n = 9) > SCA40 > or = levcromakalim (6.49 +/- 0.04; n = 6) > SKF94120 (5.87 +/- 0.10; n = 9). 2. When tested against the activity of the isoenzymes of cyclic nucleotide phosphodiesterase (PDE) isolated from human bronchus, SCA40 proved highly potent against PDE III (-log IC50 = 6.47 +/- 0.16; n = 4). It was markedly less potent against PDE IV (4.82 +/- 0.18; n = 4) and PDE V (4.32 +/- 0.11; n = 4). 3. Human polymorphonuclear leukocytes (PMNs) stimulated with N-formylmethionyl-leucyl-phenylalanine (FMLP) produced a concentration-dependent superoxide anion generation and elastase release. SCA40 (1 nM-10 microM) produced a concentration-related inhibition of FMLP (30 nM approximately EC50)-induced superoxide production (-log IC50 = 5.48 +/- 0.10; n = 6) and elastase release (-log IC50 = 5.50 +/- 0.26; n = 6). Rolipram was an effective inhibitor of superoxide generation and elastase release (-log IC50 values approximately 8) while SKF94120 and levcromakalim were scarcely effective. 4. FMLP (30 nM) and thimerosal (20 microM) induced leukotriene B4 production and elevation of intracellular calcium concentration in human PMNs. The production of leukotriene B4 was inhibited by SCA40 in a concentration-related manner (-log IC50 = 5.94 +/- 0.22; n = 6) but SCA40 was less effective against the elevation of intracellular calcium. Rolipram was an effective inhibitor of leukotriene B4 synthesis (-log IC50 approximately 7) and intracellular calcium elevation (-log IC50 approximately 6) while SKF94120 and levcromakalim were scarcely effective. 5. It is concluded that SCA40 is an effective inhibitor of the inherent tone of human isolated bronchus. The bronchodilatation produced by SCA40 appears mainly related to PDE inhibition since the potency of SCA40 as a relaxant of human isolated bronchus was found to be close to its potency as inhibitor of PDE III activity isolated from human bronchus. In addition, SCA40 exhibited inhibitory effects on human PMN function stimulated by FMLP. These effects may be related to the ability of SCA40 to inhibit PDE IV from human PMNs while the contribution of PDE V inhibition is uncertain. We found no evidence of a role for levcromakalim-sensitive plasmalemmal K+-channels in human PMNs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8872362      PMCID: PMC1915727          DOI: 10.1111/j.1476-5381.1996.tb15682.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  39 in total

1.  The action of a potassium channel activator, BRL 38227 (lemakalim), on human airway smooth muscle.

Authors:  J L Black; C L Armour; P R Johnson; L A Alouan; P J Barnes
Journal:  Am Rev Respir Dis       Date:  1990-12

2.  Differential inhibition and potentiation of chemoattractant-induced superoxide formation in human neutrophils by the cell-permeant analogue of cyclic GMP, N2,2'-O-dibutyryl guanosine 3':5'-cyclic monophosphate.

Authors:  J Ervens; G Schultz; R Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-04       Impact factor: 3.000

3.  Inhibition by manoalide of fMLP-stimulated elastase release from human neutrophils.

Authors:  G W De Vries; L D Amdahl; K D Kramer; L A Wheeler
Journal:  Biochem Pharmacol       Date:  1990-12-01       Impact factor: 5.858

4.  Zardaverine as a selective inhibitor of phosphodiesterase isozymes.

Authors:  C Schudt; S Winder; B Müller; D Ukena
Journal:  Biochem Pharmacol       Date:  1991-06-21       Impact factor: 5.858

Review 5.  Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors.

Authors:  J A Beavo; D H Reifsnyder
Journal:  Trends Pharmacol Sci       Date:  1990-04       Impact factor: 14.819

6.  Influence of selective phosphodiesterase inhibitors on human neutrophil functions and levels of cAMP and Cai.

Authors:  C Schudt; S Winder; S Forderkunz; A Hatzelmann; V Ullrich
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-12       Impact factor: 3.000

7.  The presence of five cyclic nucleotide phosphodiesterase isoenzyme activities in bovine tracheal smooth muscle and the functional effects of selective inhibitors.

Authors:  M Shahid; R G van Amsterdam; J de Boer; R E ten Berge; C D Nicholson; J Zaagsma
Journal:  Br J Pharmacol       Date:  1991-10       Impact factor: 8.739

8.  A comparison of the effects of SCA40, NS 004 and NS 1619 on large conductance Ca(2+)-activated K+ channels in bovine tracheal smooth muscle cells in culture.

Authors:  S Macmillan; R D Sheridan; E R Chilvers; L Patmore
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

9.  Role of low Km cyclic AMP phosphodiesterase inhibition in tracheal relaxation and bronchodilation in the guinea pig.

Authors:  A L Harris; M J Connell; E W Ferguson; A M Wallace; R J Gordon; E D Pagani; P J Silver
Journal:  J Pharmacol Exp Ther       Date:  1989-10       Impact factor: 4.030

10.  A quantitative investigation into the dependence of Ca2+ mobilisation on changes in inositol 1,4,5-trisphosphate levels in the stimulated neutrophil.

Authors:  N T Thompson; R W Bonser; J E Tateson; G D Spacey; R W Randall; H F Hodson; L G Garland
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 8.739

View more
  4 in total

1.  Bronchodilator and anti-inflammatory activities of glaucine: In vitro studies in human airway smooth muscle and polymorphonuclear leukocytes.

Authors:  J Cortijo; V Villagrasa; R Pons; L Berto; M Martí-Cabrera; M Martinez-Losa; T Domenech; J Beleta; E J Morcillo
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

2.  Roflumilast N-oxide, a PDE4 inhibitor, improves cilia motility and ciliated human bronchial epithelial cells compromised by cigarette smoke in vitro.

Authors:  J Milara; M Armengot; P Bañuls; H Tenor; Rolf Beume; E Artigues; J Cortijo
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

3.  The effects of phosphodiesterase type 4 inhibitors on tumour necrosis factor-alpha and leukotriene B4 in a novel human whole blood assay.

Authors:  C Brideau; C Van Staden; A Styhler; I W Rodger; C C Chan
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

4.  Airways disease: phenotyping heterogeneity using measures of airway inflammation.

Authors:  Salman Siddiqui; Christopher E Brightling
Journal:  Allergy Asthma Clin Immunol       Date:  2007-06-15       Impact factor: 3.406

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.